ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J. Souers, Steven W. Elmore, Joel D. Leverson et al.|Nature Medicine|2013Cited by 3k
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathwaysGeorg Lenz, Louis M. Staudt, Andreas Rosenwald et al.|Proceedings of the National Academy of Sciences|2008Cited by 985
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren Lasko, Kenneth D. Bromberg, Clarissa G. Jakob et al.|Nature|2017Cited by 853
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancerEmily J. Faivre, Yu Shen, Keith F. McDaniel et al.|Nature|2020Cited by 404
Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208Andrew J. Souers, Steven W. Elmore, Erwin R. Boghaert et al.|Unknown|2013Cited by 182